Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management Delphine Trousse, MD, Fabrice Barlesi,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance.

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Type D Personality in Gastric Cancer Survivors: Association With Poor Quality of Life, Overall Survival, and Mental Health Jia-kui Zhang, MD, Li-li Fang,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer David R. Gandara, MD, Natasha.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor.

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Anne S. Tsao, MD, Suyu Liu, PhD, J. Jack Lee, PhD, Christine M

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non–Small-Cell Lung Cancer Ho-Shin.

European Lung Cancer Conference (ELCC) 2016 Organisation

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Mark A. Socinski, MD Journal of Thoracic Oncology

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC Alain Vergnenegre, MD, PhD, Bartomeu Massuti,

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC Fabrice Barlesi, MD, PhD, Edward B. Garon, MD, Dong-Wan Kim, MD, Enriqueta Felip, MD, Ji-Youn Han, MD, Joo-Hang Kim, MD, Myung-Ju Ahn, MD, Mary Jo Fidler, MD, Matthew A. Gubens, MD, Gilberto de Castro, PhD, Veerle Surmont, MD, Qiao Li, PhD, Anne C. Deitz, PhD, Gregory M. Lubiniecki, MD, Roy S. Herbst, MD Journal of Thoracic Oncology Volume 14, Issue 5, Pages 793-801 (May 2019) DOI: 10.1016/j.jtho.2019.01.016 Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Proportion of patients with deteriorated or improved status in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 scores at week 12 in patients with NSCLC tumor proportion score 1% or greater. Multiple imputation based on missing at random assumption was used. Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Change from baseline to week 12 in (A) European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) and (B) European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) symptoms in patients with programmed death-ligand 1 tumor proportion score 1% or greater (full analysis set population) treated with pembrolizumab 2 mg/kg or docetaxel. Error bars are 95% confidence intervals. Q3W, every 3 weeks. Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1A Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1B Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2A Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2B Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3 Journal of Thoracic Oncology 2019 14, 793-801DOI: (10.1016/j.jtho.2019.01.016) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions